E. Eric Tokat retweeted
Super excited about this deal! 👏👏👏
The team at Merida pioneered an innovative approach to deplete pathogenic autoantibodies for autoimmune disease and allergy.
@EliLillyandCo will help make this transformative approach a reality for patients!
Congrats to Adam Townsend, Dario Gutierrez, Dodzie Sogah, and the entire Merida team!
Eli Lilly has agreed to pay up to $2.875 billion in cash for biotechnology company Merida Biosciences in a deal that bolsters the drugmaker’s immunology portfolio. on.wsj.com/3T45gqU
Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B
Inhibrx, Inc. shareholders will receive $30/sh in cash, a $5 CVR, 0.25 shares in New Inhibrx, a new publicly traded company that retains all non-101 assets of Inhibrx prnewswire.com/news-releases…
Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B
Inhibrx, Inc. shareholders will receive $30/sh in cash, a $5 CVR, 0.25 shares in New Inhibrx, a new publicly traded company that retains all non-101 assets of Inhibrx prnewswire.com/news-releases…
Centerview Partners acted as Financial Advisor to Ambrx on its sale to Johnson & Johnson
Ambrx to be acquired by Johnson & Johnson for $28/sh, or $2bn businesswire.com/news/home/2…
Ambrx to be acquired by Johnson & Johnson for $28/sh, or $2bn businesswire.com/news/home/2…
Centerview Partners acted as Exclusive Financial Advisor to Harpoon on its sale to Merck
$HARP Harpoon Therapeutics to be acquired by Merck $MRK for $23/sh, or $680M businesswire.com/news/home/2…
$HARP Harpoon Therapeutics to be acquired by Merck $MRK for $23/sh, or $680M businesswire.com/news/home/2…
Centerview Partners acted as Exclusive Financial Advisor to RayzeBio on its sale to Bristol Myers Squibb
$RYZB RayzeBio to be acquired by Bristol Myers Squibb for $62.50/sh, or $4.1bn $BMS news.bms.com/news/details/20…
$RYZB RayzeBio to be acquired by Bristol Myers Squibb for $62.50/sh, or $4.1bn $BMS news.bms.com/news/details/20…
Centerview Partners acted as Exclusive Financial Advisor to Gracell on its sale to AstraZeneca
$GRCL Gracell Biotechnologies to be acquired by AstraZeneca for $10+$1.50CVR, or up to $1.2bn $AZN ir.gracellbio.com/news-relea…
$GRCL Gracell Biotechnologies to be acquired by AstraZeneca for $10+$1.50CVR, or up to $1.2bn $AZN ir.gracellbio.com/news-relea…
Centerview Partners acted as Exclusive Financial Advisor to Icosavax on its sale to AstraZeneca
AstraZeneca to acquire Icosavax for $15+$5; or up to $1.1bn $ICVX $AZN investors.icosavax.com/news-…
AstraZeneca to acquire Icosavax for $15+$5; or up to $1.1bn $ICVX $AZN investors.icosavax.com/news-…
Centerview Partners acted as financial advisor to Cerevel Therapeutics on its sale to Abbvie
AbbVie to acquire Cerevel Therapeutics for $45/sh, or $8.7bn investors.cerevel.com/news-r…
AbbVie to acquire Cerevel Therapeutics for $45/sh, or $8.7bn investors.cerevel.com/news-r…
Centerview Partners acted as financial advisor to Carmot Therapeutics
Roche to acquire Carmot Therapeutics for up to $3.1bn; or $2.7bn upfront plus $400M in Milestones carmot.us/carmot-therapeutic…
Roche to acquire Carmot Therapeutics for up to $3.1bn; or $2.7bn upfront plus $400M in Milestones carmot.us/carmot-therapeutic…
Centerview Partners acted as Financial Advisor to Forge Biologics on its sale to Ajinomoto Co.
Ajinomoto Co. to Acquire Forge Biologics for $620 Million forgebiologics.com/ajinomoto…
Ajinomoto Co. to Acquire Forge Biologics for $620 Million forgebiologics.com/ajinomoto…
Centerview Partners acted as Exclusive Financial Advisor to POINT Biopharma on its sale to Lilly
Lilly to acquire POINT Biopharma for $12.50/share, or $1.4bn $LLY $PNT investor.lilly.com/news-rele…



